A T-cell receptor capable of binding to HPV16 E6 antigen presented by HLA-C*14:02 molecules and its application

By designing T-cell receptors for HPV16 E6 antigens presented by HLA-C*14:02 molecules with specific TCRα and β chains, the treatment gap for HLA-C*14:02 genotype cervical cancer patients was filled, achieving highly efficient killing of HPV16-positive cervical cancer cells and expanding the applicability of TCR-T therapy.

CN122080174BActive Publication Date: 2026-06-30SUZHOU INST OF SYST MEDICINE
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
SUZHOU INST OF SYST MEDICINE
Filing Date
2026-04-23
Publication Date
2026-06-30

AI Technical Summary

Technical Problem

Currently, there are no reports of T-cell receptors that specifically recognize the HPV16 E6 antigen presented by the HLA-C*14:02 molecule, which limits the application of TCR-T therapy in patients with HLA-C*14:02 genotype cervical cancer.

Method used

A T-cell receptor (TCR) was designed and synthesized, which contains specific amino acid sequences of the complementary determinant region (CDR) of the TCRα and β chains. It can bind with high affinity and high specificity to the HPV16 E6 antigen presented by the HLA-C*14:02 molecule and is introduced into T cells via a retroviral vector to form TCR-T cells for killing HPV16 positive cervical cancer cells.

Benefits of technology

This TCR-T cell can effectively recognize and kill HPV16 E6 antigen presented by the HLA-C*14:02 molecule, significantly expanding the applicable population for TCR-T therapy and providing a precision immunotherapy strategy for patients with HLA-C*14:02 genotype cervical cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122080174B_ABST
    Figure CN122080174B_ABST
Patent Text Reader

Abstract

This invention relates to a T-cell receptor capable of binding to the HPV16 E6 antigen presented by the HLA-C*14:02 molecule. The T-cell receptor comprises: αCDR1 (amino acid sequence as shown in SEQ ID NO:1), αCDR2 (amino acid sequence as shown in SEQ ID NO:3), αCDR3 (amino acid sequence as shown in SEQ ID NO:5), βCDR1 (amino acid sequence as shown in SEQ ID NO:11), βCDR2 (amino acid sequence as shown in SEQ ID NO:13), and βCDR3 (amino acid sequence as shown in SEQ ID NO:15). This invention provides a novel and precise immunotherapy strategy for patients with HLA-C*14:02 genotype HPV-related cervical cancer, significantly expanding the applicable population for TCR-T therapy.
Need to check novelty before this filing date? Find Prior Art